Our platform leverages artificial intelligence to offer predictive insights critical for peptide drug development, encompassing a comprehensive suite of services.

[A] Protein Structure Prediction, Protein Interaction Forecasting

We deliver advanced predictions on protein structures and the interaction sites for protein binding, utilizing cutting-edge artificial intelligence technologies.

[B] Protein-Ligand Binding Site and Force Prediction

Our services include detailed predictions on protein-drug (ligand) binding sites and binding force, essential for understanding drug efficacy and interactions.

[C] Therapeutic Target Identification via Machine Learning and Network Models

We provide vital diagnostic and therapeutic target information, employing sophisticated machine learning and network models to identify promising targets.

[D] Peptide Drug Design from Protein Structures

Our peptide drug design services are grounded in deep knowledge of protein structures, necessitating the use of advanced technological solutions.

[E] Predicting Peptide Drug Efficacy with Network Modeling

We offer predictions on the effects of drugs, including inhibitory actions, based on robust network models, facilitating the development of effective therapeutics.

[F] Off-Target Effect Prediction for New Peptide Drugs

Our capabilities extend to providing off-target prediction information for new peptide drugs, a process that requires significant technological innovation.

[G] Optimal E3-Ubiquitin Ligase Selection for PROTAC/AUTOTAC/DUOTAC Strategies

We specialize in predicting the optimal E3-ubiquitin ligase for the application of target protein degradation and stability technologies such as PROTAC, AUTOTAC, and DUOTAC, highlighting our commitment to technical excellence.

[H] Preclinical Evaluation through In-Silico Simulation

Our platform supports drug development with in-silico simulation results for preclinical evaluation, enabling early assessment of drug viability.

[I] Clinical Evaluation via In-Silico Simulation Simulation

Additionally, we provide in-silico simulation results for clinical evaluation, supporting the progression from preclinical stages to clinical trials.

Our offerings encompass a broad range of services focused on structural proteins and the intricate network of protein-protein interactions within various biological matrices such as cells, tissues, and blood.

[A] Structural Proteome and Interactome Data Generation

We have developed a robust technology capable of screening for alterations in over 4,000 protein structures in blood and 12,000 in tissues and cell lines. This is achieved through the application of cutting-edge methods including Chemical Proteomics Profiling (CPP), Limited Proteolysis (LiP), and Hydrogen/Deuterium Exchange (HDX).

[B] Protein Interaction Partner Verification

Our technology also enables the validation of interaction partners of target proteins. This is accomplished by employing various cross-linkers in conjunction with Cross-Linking Mass Spectrometry (XL-MS) techniques, ensuring precise identification of interacting proteins.

[C] Target Drug-Binding Site Identification

We possess sophisticated technology that allows for the detection of target drug-binding sites on proteins with over 92% accuracy. This is facilitated through the use of CPP, LiP, Thermal Proteome Profiling (TPP), and HDX methodologies, highlighting our commitment to precision and reliability.

[D] Drug-Induced Enzyme Activity Screening

Our capabilities extend to the high-throughput screening of enzyme activity, with the ability to simultaneously assess the activity of 6,241 proteins acting as enzymes in the human body. This is achieved through the use of proximity-labeling techniques such as APEX and Activity-Based Protein Profiling (ABPP), offering comprehensive insights into enzymatic responses to drug treatments.

[E] Antibody Binding Site Identification

We offer specialized technology for the discovery of antibody binding sites, utilizing CPP or HDX methods. This technology supports the development of targeted antibody therapies by precisely identifying binding sites on proteins.

[F] In Vitro Preclinical Drug Analysis in Cell Lines

Our acquired technology enables the thorough evaluation of drug efficacy and toxicity in cell lines, providing critical insights during the preclinical development phase.

[G] In Vivo Preclinical PK and PD Analysis in Animal Models

We have secured technology that supports comprehensive preclinical analysis of PK and PD in animal model samples, facilitating the translation of research findings into potential therapeutic applications.